{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:58:12Z","timestamp":1781567892982,"version":"3.54.5"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81601780"],"award-info":[{"award-number":["81601780"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31601002"],"award-info":[{"award-number":["31601002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Science and Technology Innovation Action Plan","award":["19JC1416500"],"award-info":[{"award-number":["19JC1416500"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The fast-declining clinical efficacy of dihydroartemisinin-piperaquine (DHA-PPQ) in Cambodia is a warning of the underlying westward dissemination of piperaquine resistance in the Greater Mekong Subregion (GMS). Mutations in the <jats:italic>Plasmodium falciparum<\/jats:italic> Kelch 13-propeller (PfK13) and the <jats:italic>P. falciparum<\/jats:italic> chloroquine resistance transporter (PfCRT), as well as <jats:italic>plasmepsin<\/jats:italic> 2\/3 gene amplification, have been discovered as molecular markers for predicting DHA-PPQ treatment failure. Determining whether these genetic variations of <jats:italic>P. falciparum<\/jats:italic> are linked to DHA-PPQ resistance is critical, especially along the China\u2013Myanmar (CM) border, where PPQ has been utilized for decades.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 173 <jats:italic>P. falciparum<\/jats:italic> samples of dried blood spots (DBS) were collected along the CM border between 2007 and 2010, the Thailand\u2013Cambodia (TC) border between 2009 and 2013, and the Thailand\u2013Myanmar (TM) border between 2012 and 2014. PCR and sequencing were used to identified PfCRT mutations, while qPCR was used to determine the copy number of <jats:italic>plasmepsin<\/jats:italic> 2\/3. The prevalence of DHA-PPQ resistance in three locations was investigated using data paired with K13 mutations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Three fragments of the <jats:italic>pfcrt<\/jats:italic> gene were amplified for all 173 samples, and seven SNPs were identified (M74I, N75E\/D, K76T, H97L, I218F, A220S, I356L). No new PfCRT mutations conferring resistance to PPQ (T93S, H97Y, F145I, M343L, and G353V) were discovered, except for one mutant I218F identified in the TM border (2.27%, 1\/44). Additionally, mutant H97L was found in the TC, TM, and CM borders at 3.57% (1\/28), 6.82% (3\/44), and 1% (1\/101), respectively. A substantial K13 C580Y variant prevalence was found in the TC and TM border, accounting for 64.29% (18\/28) and 43.18% (19\/44), respectively, while only 1% (1\/101) was found in the CM border. The K13 F446I variant was only identified and found to reach a high level (28.71%, 29\/101) in the CM border. Furthermore, 10.71% (3\/28) of TC isolates and 2.27% (1\/44) of TM isolates carried more than one copy of <jats:italic>plasmepsin<\/jats:italic> 2\/3 and K13 C580Y variant, while no <jats:italic>plasmepsin<\/jats:italic> 2\/3 amplification was identified in the CM isolates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Compared with the <jats:italic>P. falciparum<\/jats:italic> samples collected from the TC and TM borders, fewer parasites carried <jats:italic>plasmepsin<\/jats:italic> 2\/3 amplification and novel PfCRT variants, while more parasites carried predominant K13 mutations at position F446I, in the CM border. Clear evidence of DHA-PPQ resistance associated with candidate markers was not found in this border region suggesting a further evaluation of these markers and continuous surveillance is warranted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s13071-022-05239-1","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T11:04:19Z","timestamp":1649761459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Evaluations of candidate markers of dihydroartemisinin-piperaquine resistance in Plasmodium falciparum isolates from the China\u2013Myanmar, Thailand\u2013Myanmar, and Thailand\u2013Cambodia borders"],"prefix":"10.1186","volume":"15","author":[{"given":"Run","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0629-3057","authenticated-orcid":false,"given":"Yilong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"5239_CR1","unstructured":"WHO. World Malaria Report 2020. Geneva: World Health Organization; 2020.\u00a0https:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2020\/report\/en\/. Accessed 20 Aug 2021."},{"key":"5239_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/01.qco.0000186848.46417.6c","volume":"18","author":"EA Ashley","year":"2005","unstructured":"Ashley EA, White NJ. Artemisinin-based combinations. Curr Opin Infect Dis. 2005;18:531\u20136.","journal-title":"Curr Opin Infect Dis"},{"key":"5239_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nature15535","volume":"526","author":"S Bhatt","year":"2015","unstructured":"Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526:207\u201311.","journal-title":"Nature"},{"key":"5239_CR4","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMc0805011","volume":"359","author":"H Noedl","year":"2008","unstructured":"Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Artemisinin resistance in Cambodia 1 (ARC1) study consortium. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619\u201320.","journal-title":"N Engl J Med"},{"key":"5239_CR5","doi-asserted-by":"crossref","unstructured":"Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361(5):455\u201367. Erratum in: N\u00a0Engl\u00a0J Med. 2009;361(17):1714.","DOI":"10.1056\/NEJMoa0808859"},{"key":"5239_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1473-3099(12)70181-0","volume":"12","author":"C Amaratunga","year":"2012","unstructured":"Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 2012;12:851\u20138.","journal-title":"Lancet Infect Dis"},{"key":"5239_CR7","doi-asserted-by":"crossref","unstructured":"Ashley EA,\u00a0Dhorda\u00a0M, Fairhurst RM,\u00a0Amaratunga\u00a0C, Lim P,\u00a0Suon\u00a0S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N\u00a0Engl\u00a0J Med. 2014;371(5):411\u201323.\u00a0Erratum in: N\u00a0Engl\u00a0J Med. 2014;371(8):786.","DOI":"10.1056\/NEJMx140047"},{"key":"5239_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/1475-2875-11-355","volume":"11","author":"TT Hien","year":"2012","unstructured":"Hien TT, Thuy-Nhien NT, Phu NH, Boni MF, Thanh NV, Nha-Ca NT, et al. In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province. Vietnam Malar J. 2012;11:355.","journal-title":"Vietnam Malar J"},{"key":"5239_CR9","first-page":"201","volume":"44","author":"MD Bustos","year":"2013","unstructured":"Bustos MD, Wongsrichanalai C, Delacollette C, Burkholder B. Monitoring antimalarial drug efficacy in the Greater Mekong Subregion: an overview of in vivo results from 2008 to 2010. Southeast Asian J Trop Med Public Health. 2013;44:201\u201330 (discussion 306-7).","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"5239_CR10","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/S0140-6736(12)60484-X","volume":"379","author":"AP Phyo","year":"2012","unstructured":"Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960\u20136.","journal-title":"Lancet"},{"key":"5239_CR11","doi-asserted-by":"publisher","first-page":"e57689","DOI":"10.1371\/journal.pone.0057689","volume":"8","author":"MP Kyaw","year":"2013","unstructured":"Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Aye MM, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS ONE. 2013;8:e57689.","journal-title":"PLoS ONE"},{"key":"5239_CR12","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/infdis\/jiv249","volume":"212","author":"F Huang","year":"2015","unstructured":"Huang F, Takala-Harrison S, Jacob CG, Liu H, Sun X, Yang H, et al. A single mutation in K13 predominates in Southern China and Is associated with delayed clearance of Plasmodium falciparum following artemisinin treatment. J Infect Dis. 2015;212:1629\u201335.","journal-title":"J Infect Dis"},{"key":"5239_CR13","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/infdis\/jiu491","volume":"211","author":"S Takala-Harrison","year":"2015","unstructured":"Takala-Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp AM, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis. 2015;211:670\u20139.","journal-title":"J Infect Dis"},{"key":"5239_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1473-3099(15)00487-9","volume":"16","author":"C Amaratunga","year":"2016","unstructured":"Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016;16:357\u201365.","journal-title":"Lancet Infect Dis"},{"key":"5239_CR15","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3201\/eid1405.071601","volume":"14","author":"C Wongsrichanalai","year":"2008","unstructured":"Wongsrichanalai C, Meshnick SR. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis. 2008;14:716\u20139.","journal-title":"Emerg Infect Dis"},{"key":"5239_CR16","doi-asserted-by":"crossref","unstructured":"Saunders DL,\u00a0Vanachayangkul\u00a0P, Lon C; U.S. Army Military Malaria Research Program; National Center for Parasitology, Entomology, and Malaria Control (CNM); Royal Cambodian Armed Forces.\u00a0Dihydroartemisinin-piperaquine failure in Cambodia. N\u00a0Engl\u00a0J Med. 2014;371(5):484\u20135.","DOI":"10.1056\/NEJMc1403007"},{"key":"5239_CR17","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1128\/AAC.00835-15","volume":"59","author":"R Leang","year":"2015","unstructured":"Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of Plasmodium falciparum Malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015;59:4719\u201326.","journal-title":"Antimicrob Agents Chemother"},{"key":"5239_CR18","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S1473-3099(15)70049-6","volume":"15","author":"MD Spring","year":"2015","unstructured":"Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015;15:683\u201391.","journal-title":"Lancet Infect Dis"},{"key":"5239_CR19","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","volume":"19","author":"RW van der Pluijm","year":"2019","unstructured":"van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis. 2019;19:952\u201361.","journal-title":"Lancet Infect Dis"},{"key":"5239_CR20","doi-asserted-by":"crossref","unstructured":"Imwong\u00a0M,\u00a0Suwannasin\u00a0K,\u00a0Kunasol\u00a0C,\u00a0Sutawong\u00a0K,\u00a0Mayxay\u00a0M,\u00a0Rekol\u00a0H, et al. The spread of artemisinin-resistant\u00a0Plasmodium falciparum\u00a0in the Greater Mekong subregion: a molecular epidemiology observational study. Lancet Infect Dis. 2017;17(5):491\u20137. Erratum in: Lancet Infect Dis. 2017;17(5):475.","DOI":"10.1016\/S1473-3099(17)30048-8"},{"key":"5239_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12936-017-1680-8","volume":"16","author":"NV Thanh","year":"2017","unstructured":"Thanh NV, Thuy-Nhien N, Tuyen NT, Tong NT, Nha-Ca NT, Dong LT, et al. Rapid decline in the susceptibility of to dihydroartemisinin-piperaquine in the south of Vietnam. Malar J. 2017;16:27.","journal-title":"Malar J"},{"key":"5239_CR22","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S1473-3099(17)30524-8","volume":"17","author":"M Imwong","year":"2017","unstructured":"Imwong M, Hien TT, Thuy-Nhien NT, Dondorp AM, White NJ. Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam. Lancet Infect Dis. 2017;17:1022\u20133.","journal-title":"Lancet Infect Dis"},{"key":"5239_CR23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","volume":"395","author":"RW van der Pluijm","year":"2020","unstructured":"van der Pluijm RW, Tripura R, Hoglund RM, Pyae Phyo A, Lek D, Ul Islam A, et al. Tracking Resistance to Artemisinin Collaboration. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet. 2020;395:1345\u201360.","journal-title":"Lancet"},{"key":"5239_CR24","doi-asserted-by":"publisher","first-page":"e01689","DOI":"10.1128\/AAC.01689-16","volume":"61","author":"W Zeng","year":"2017","unstructured":"Zeng W, Bai Y, Wang M, Wang Z, Deng S, Ruan Y, et al. Significant divergence in sensitivity to antimalarial drugs between neighboring Plasmodium falciparum populations along the Eastern Border of Myanmar. Antimicrob Agents Chemother. 2017;61:e01689-e1716.","journal-title":"Antimicrob Agents Chemother"},{"key":"5239_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12936-015-0672-9","volume":"14","author":"Z Wang","year":"2015","unstructured":"Wang Z, Shrestha S, Li X, Miao J, Yuan L, Cabrera M, et al. Prevalence of K13-propeller polymorphisms in Plasmodium falciparum from China\u2013Myanmar border in 2007\u20132012. Malar J. 2015;14:168.","journal-title":"Malar J"},{"key":"5239_CR26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1473-3099(15)70032-0","volume":"15","author":"KM Tun","year":"2015","unstructured":"Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15:415\u201321.","journal-title":"Lancet Infect Dis"},{"key":"5239_CR27","doi-asserted-by":"publisher","first-page":"285.e1","DOI":"10.1016\/j.cmi.2015.10.027","volume":"22","author":"C Putaporntip","year":"2016","unstructured":"Putaporntip C, Kuamsab N, Kosuwin R, Tantiwattanasub W, Vejakama P, Sueblinvong T, et al. Natural selection of K13 mutants of Plasmodium falciparum in response to artemisinin combination therapies in Thailand. Clin Microbiol Infect. 2016;22:285.e1-8.","journal-title":"Clin Microbiol Infect"},{"key":"5239_CR28","doi-asserted-by":"publisher","first-page":"20100","DOI":"10.1038\/srep20100","volume":"6","author":"R Ye","year":"2016","unstructured":"Ye R, Hu D, Zhang Y, Huang Y, Sun X, Wang J, et al. Distinctive origin of artemisinin-resistant Plasmodium falciparum on the China\u2013Myanmar border. Sci Rep. 2016;6:20100.","journal-title":"Sci Rep"},{"key":"5239_CR29","doi-asserted-by":"publisher","first-page":"e1004789","DOI":"10.1371\/journal.ppat.1004789","volume":"11","author":"E Talundzic","year":"2015","unstructured":"Talundzic E, Okoth SA, Congpuong K, Plucinski MM, Morton L, Goldman IF, et al. Selection and spread of artemisinin-resistant alleles in Thailand prior to the global artemisinin resistance containment campaign. PLoS Pathog. 2015;11:e1004789.","journal-title":"PLoS Pathog"},{"key":"5239_CR30","unstructured":"WHO.\u00a0Status report: artemisinin resistance and artemisinin-based combination therapy efficacy.\u00a0Geneva: World Health Organization; 2018. https:\/\/apps.who.int\/iris\/handle\/10665\/255213?locale-attribute=en&. Accessed 12 Sep 2021."},{"key":"5239_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50\u20135.","journal-title":"Nature"},{"key":"5239_CR32","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1473-3099(16)30409-1","volume":"17","author":"R Amato","year":"2017","unstructured":"Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, et al. Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. Lancet Infect Dis. 2017;17:164\u201373.","journal-title":"Lancet Infect Dis"},{"key":"5239_CR33","doi-asserted-by":"crossref","unstructured":"Witkowski B,\u00a0Duru\u00a0V,\u00a0Khim\u00a0N, Ross LS,\u00a0Saintpierre\u00a0B,\u00a0Beghain\u00a0J, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis. 2017;17(2):174\u201383. Erratum in: Lancet Infect Dis. 2018;18(8):829.","DOI":"10.1016\/S1473-3099(16)30415-7"},{"key":"5239_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1473-3099(18)30068-9","volume":"18","author":"R Amato","year":"2018","unstructured":"Amato R, Pearson RD, Almagro-Garcia J, Amaratunga C, Lim P, Suon S, et al. Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study. Lancet Infect Dis. 2018;18:337\u201345.","journal-title":"Lancet Infect Dis"},{"key":"5239_CR35","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/gbe\/evx126","volume":"9","author":"CM Parobek","year":"2017","unstructured":"Parobek CM, Parr JB, Brazeau NF, Lon C, Chaorattanakawee S, Gosi P, et al. Partner-drug resistance and population substructuring of artemisinin-resistant Plasmodium falciparum in Cambodia. Genome Biol Evol. 2017;9:1673\u201386.","journal-title":"Genome Biol Evol"},{"key":"5239_CR36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12916-015-0539-5","volume":"13","author":"V Duru","year":"2015","unstructured":"Duru V, Khim N, Leang R, Kim S, Domergue A, Kloeung N, et al. Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations. BMC Med. 2015;13:305.","journal-title":"BMC Med"},{"key":"5239_CR37","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1038\/s41467-018-05652-0","volume":"9","author":"LS Ross","year":"2018","unstructured":"Ross LS, Dhingra SK, Mok S, Yeo T, Wicht KJ, K\u00fcmpornsin K, et al. Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine. Nat Commun. 2018;9:3314.","journal-title":"Nat Commun"},{"key":"5239_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2165\/00003495-200565010-00004","volume":"65","author":"TM Davis","year":"2005","unstructured":"Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. Piperaquine: a resurgent antimalarial drug. Drugs. 2005;65:75\u201387.","journal-title":"Drugs"},{"key":"5239_CR39","first-page":"198","volume":"10","author":"HL Yang","year":"1992","unstructured":"Yang HL, Yang PF, Liu DQ, Liu RJ, Dong Y, Zhang CY, et al. Sensitivity in vitro of Plasmodium falciparum to chloroquine, pyronaridine, artesunate and piperaquine in south Yunnan. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1992;10:198\u2013200 (Chinese).","journal-title":"Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi"},{"key":"5239_CR40","first-page":"43","volume":"17","author":"H Yang","year":"1999","unstructured":"Yang H, Liu D, Huang K, Yang Y, Yang P, Liao M, et al. Assay of sensitivity of Plasmodium falciparum to chloroquine, amodiaquine, piperaquine, mefloquine and quinine in Yunnan province. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1999;17:43\u20135 (Chinese).","journal-title":"Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi"},{"key":"5239_CR41","unstructured":"Guo XB. Randomized comparison on the treatment of falciparum malaria with\u00a0dihydroartemisinin\u00a0and piperaquine.\u00a0Zhonghua\u00a0Yi\u00a0Xue\u00a0Za\u00a0Zhi. 1993;73:602-4, 638"},{"key":"5239_CR42","doi-asserted-by":"publisher","first-page":"577","DOI":"10.4269\/ajtmh.15-0029","volume":"93","author":"Y Wang","year":"2015","unstructured":"Wang Y, Yang Z, Yuan L, Zhou G, Parker D, Lee MC, et al. Clinical efficacy of dihydroartemisinin\u2013piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria at the China\u2013Myanmar border. Am J Trop Med Hyg. 2015;93:577\u201383.","journal-title":"Am J Trop Med Hyg"},{"key":"5239_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12936-015-0584-8","volume":"14","author":"H Liu","year":"2015","unstructured":"Liu H, Yang HL, Tang LH, Li XL, Huang F, Wang JZ, et al. In vivo monitoring of dihydroartemisinin-piperaquine sensitivity in Plasmodium falciparum along the China\u2013Myanmar border of Yunnan Province, China from 2007 to 2013. Malar J. 2015;14:47.","journal-title":"Malar J"},{"key":"5239_CR44","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/s41467-018-04104-z","volume":"9","author":"S Bopp","year":"2018","unstructured":"Bopp S, Magistrado P, Wong W, Schaffner SF, Mukherjee A, Lim P, et al. Plasmepsin II-III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum. Nat Commun. 2018;9:1769.","journal-title":"Nat Commun"},{"key":"5239_CR45","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/molbev\/msy096","volume":"35","author":"S Kumar","year":"2018","unstructured":"Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol. 2018;35:1547\u20139.","journal-title":"Mol Biol Evol"},{"key":"5239_CR46","unstructured":"Hall T. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/NT. 1999. Nucleic acids symposium series 41:95\u20138.\u00a0http:\/\/www.mbio.ncsu.edu\/BioEdit\/bioedit.html. Accessed 30 Aug 2021."},{"key":"5239_CR47","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1093\/bioinformatics\/btp187","volume":"25","author":"P Librado","year":"2009","unstructured":"Librado P, Rozas J. DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. Bioinformatics. 2009;25:1451\u20132.","journal-title":"Bioinformatics"},{"key":"5239_CR48","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/oxfordjournals.molbev.a026036","volume":"16","author":"HJ Bandelt","year":"1999","unstructured":"Bandelt HJ, Forster P, R\u00f6hl A. Median-joining networks for inferring intraspecific phylogenies. Mol Biol Evol. 1999;16:37\u201348.","journal-title":"Mol Biol Evol"},{"key":"5239_CR49","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/S1473-3099(19)30543-2","volume":"19","author":"SK Dhingra","year":"2019","unstructured":"Dhingra SK, Small-Saunders JL, M\u00e9nard D, Fidock DA. Plasmodium falciparum resistance to piperaquine driven by PfCRT. Lancet Infect Dis. 2019;19:1168\u20139.","journal-title":"Lancet Infect Dis"},{"key":"5239_CR50","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/infdis\/jix334","volume":"216","author":"S Agrawal","year":"2017","unstructured":"Agrawal S, Moser KA, Morton L, Cummings MP, Parihar A, Dwivedi A, et al. Association of a novel mutation in the Plasmodium falciparum chloroquine resistance transporter with decreased piperaquine sensitivity. J Infect Dis. 2017;216:468\u201376.","journal-title":"J Infect Dis"},{"key":"5239_CR51","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/ng.2624","volume":"45","author":"O Miotto","year":"2013","unstructured":"Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet. 2013;45:648\u201355.","journal-title":"Nat Genet"},{"key":"5239_CR52","doi-asserted-by":"publisher","first-page":"e02305","DOI":"10.1128\/AAC.02305-20","volume":"65","author":"Y Si","year":"2021","unstructured":"Si Y, Zeng W, Li N, Wang C, Siddiqui F, Zhang J, et al. In vitro susceptibility of Plasmodium falciparum isolates from the China\u2013Myanmar Border Area to piperaquine and association with candidate markers. Antimicrob Agents Chemother. 2021;65:e02305-e2320.","journal-title":"Antimicrob Agents Chemother"},{"key":"5239_CR53","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1473-3099(19)30392-5","volume":"19","author":"WL Hamilton","year":"2019","unstructured":"Hamilton WL, Amato R, van der Pluijm RW, Jacob CG, Quang HH, Thuy-Nhien NT, et al. Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. Lancet Infect Dis. 2019;19:943\u201351.","journal-title":"Lancet Infect Dis"},{"key":"5239_CR54","doi-asserted-by":"crossref","unstructured":"MalariaGEN\u00a0Plasmodium falciparum Community Project. Genomic epidemiology of artemisinin resistant malaria.\u00a0Elife. 2016;5:e08714.","DOI":"10.7554\/eLife.08714"},{"key":"5239_CR55","doi-asserted-by":"publisher","first-page":"e02309","DOI":"10.1128\/AAC.02309-17","volume":"62","author":"A Mukherjee","year":"2018","unstructured":"Mukherjee A, Gagnon D, Wirth DF, Richard D. Inactivation of Plasmepsins 2 and 3 sensitizes Plasmodium falciparum to the antimalarial drug piperaquine. Antimicrob Agents Chemother. 2018;62:e02309-e2317.","journal-title":"Antimicrob Agents Chemother"},{"key":"5239_CR56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ijpddr.2018.11.004","volume":"9","author":"D Loesbanluechai","year":"2019","unstructured":"Loesbanluechai D, Kotanan N, de Cozar C, Kochakarn T, Ansbro MR, Chotivanich K, et al. Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperaquine. Int J Parasitol Drugs Drug Resist. 2019;9:16\u201322.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5239_CR57","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ijpddr.2019.04.002","volume":"10","author":"J Zhang","year":"2019","unstructured":"Zhang J, Li N, Siddiqui FA, Xu S, Geng J, Zhang J, et al. In vitro susceptibility of Plasmodium falciparum isolates from the China\u2013Myanmar border area to artemisinins and correlation with K13 mutations. Int J Parasitol Drugs Drug Resist. 2019;10:20\u20137.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5239_CR58","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12936-018-2396-0","volume":"17","author":"J Wang","year":"2018","unstructured":"Wang J, Huang Y, Zhao Y, Ye R, Zhang D, Pan W. Introduction of F446I mutation in the K13 propeller gene leads to increased ring survival rates in Plasmodium falciparum isolates. Malar J. 2018;17:248.","journal-title":"Malar J"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-022-05239-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-022-05239-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-022-05239-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T13:09:54Z","timestamp":1649768994000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-022-05239-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["5239"],"URL":"https:\/\/doi.org\/10.1186\/s13071-022-05239-1","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]},"assertion":[{"value":"29 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Internal Review Board of Naval Medical University. A consent form was obtained before individual data collection and can be provided upon request. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Declaration of Helsinki 1975, as revised in 2008.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}